Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 2491 to 2505 of 2854 results for process

  1. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued Reference number: GID-TAG436

    Technology appraisal guidance
    Discontinued

  2. Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

    Discontinued Reference number: GID-TA10698

    Technology appraisal guidance
    Discontinued

  3. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued Reference number: GID-TA10452

    Technology appraisal guidance
    Discontinued

  4. Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]

    Discontinued Reference number: GID-TA10212

    Technology appraisal guidance
    Discontinued

  5. Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

    Discontinued Reference number: GID-TA10536

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued Reference number: GID-TA10697

    Technology appraisal guidance
    Discontinued

  7. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

    Interventional procedures guidance
    Discontinued

  8. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

    Technology appraisal guidance
    Discontinued

  9. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    Discontinued Reference number: GID-TA11074

    Technology appraisal guidance
    Discontinued

  12. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    Discontinued Reference number: GID-TA10822

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    Discontinued Reference number: GID-TA10906

    Technology appraisal guidance
    Discontinued

  14. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued Reference number: GID-TA11026

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued